Molecular Vision announces new non-executive chairman
This article was originally published in Clinica
Molecular Vision (London, UK) has appointed Peter Woodford as non-executive chairman; he replaces Dr Chris Wright, who will continue to serve on the board as a non-executive director. Mr Woodford has over 35 years’ experience and joins from Roche Diagnostics, where he was responsible for the global strategic and commercial activities of the firm’s diabetes care division. His appointment is expected to strengthen the company as it prepares to commercialise its low-cost point-of-care diagnostic test technology.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.